MedTrace Logo

Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus

NCT02479698 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2026-05-20

No results posted yet for this study

Summary

This phase II trial studies how well donor cytotoxic T lymphocytes work in treating patients with malignancies with BK and/or JC virus. Cytotoxic T lymphocytes are made from donated blood cells that are grown in the laboratory and are designed to kill viruses that can cause infections in transplant patients and may be an effective treatment in patients with malignancies with BK and/or JC virus.

Conditions

  • Acquired Immunodeficiency Syndrome
  • BK Virus Infection
  • Human Immunodeficiency Virus
  • JC Virus Infection
  • Malignant Neoplasm
  • Merkel Cell Carcinoma
  • Merkel Cell Polyomavirus Infection
  • Viral Encephalitis

Interventions

BIOLOGICAL

Allogeneic BK-specific Cytotoxic T-lymphocytes

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Amanda Olson · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-23
Primary Completion
2027-07-31
Completion
2027-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02479698 on ClinicalTrials.gov